Group items tagged

In a significant event organised by Eastern Eye (EE), a sister publication of Pharmacy Business, political leaders gathered on July 1st to address pressing issues affecting the Asian community The EE election debate aimed to amplify their political voice and encourage participation in the political process. The debate, moderated by Barnie Choudhury, Editor of Eastern Eye, saw prominent figures including Andrew Boff AM of the Conservative Party, Anneliese Dodds represented Labour as Shadow Secretary of State for Women and Equalities, and Lord Richard Newby from the Liberal Democrats engaged in a robust discussion. They fielded questions on various issues affecting the UK, including economic and social inequality, immigration, health inequalities, and funding cuts to community pharmacies. Amid an audience that included stakeholders from the pharmacy sector, a notable query focused on each party's stance on the role of community pharmacies and their commitment to funding these vital services.

The Department of Health and Social Care (DHSC) will introduce new arrangements for the setting of Drug Tariff Category A reimbursement prices from April 2024. Driven by ministers, DHSC's decision aims to equalise access to margin on Category A medicines and it's part of a series of drug reimbursement reforms proposed by the department following a public consultation in 2019. Currently, prices of medicines in Category A are subject to monthly adjustment. From 1 April 2024, these will be updated quarterly based on sales and volume data obtained by DHSC under the Health Service Products (Provision and Disclosure of Information) Regulations 2018. The transition will conclude in July 2025 when the reimbursement prices will be exclusively determined by the new method. Advance notice for contractors regarding the 'new arrangements' has been outlined on the NHSBSA website. However, Community Pharmacy England (CPE) did not support the introduction of the changes at this time as pharmacies are currently grappling with "wider challenges" and there is uncertainty about the potential impact of these changes on the already "turbulent" medicines supply chain